NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against CBL & Associates Properties Inc. (“CBL” or the “Company”) (NYSE: CBL). The class action has been filed on behalf of a class consisting of all persons or entities who purchased CBL common stock between August 8, 2013 and May 24, 2016 (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that CBL made materially false and/or misleading statements and/or failed to disclose material facts about the Company, including that (1) some of its employees may have provided material non-public information to Senator Robert Corker; and (2) the Company failed to disclose to its shareholders that certain of its financing arrangements may have been obtained through fraud and/or misrepresentation.

On May 24, 2016, various news reports published that CBL was being investigated by the FBI and SEC for overstating its properties’ rental income and occupancy charges when providing those figures to banks in financing applications. Following this news, CBL stock dropped roughly 9% on May 25, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!cbl/jrmj5 or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in CBL you have until July 26, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 440972

NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares of NewLink Genetics Corporation (“NewLink” or the “Company”) (NASDAQ: NLNK) between September 17, 2013 and May 9, 2016 inclusive (the “Class Period”).

NewLink is a biopharmaceutical company that focuses on developing immunotherapeutic products, namely algenpantucel-L, to enhance treatment options for patients with cancer.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts regarding Alere’s business and operations and specifically failed to disclose that: (1) algenpantucel-L was ineffective and possibly harmful to patients; and (2) consequentially, NewLink’s public statements were materially false and misleading at all relevant times.

On Monday, May 9, 2016, NewLink’s phase III study disclosed that its experimental cancer vaccine, known as algenpantucel-L, which was designed to stimulate a patient’s immune system to recognize and kill cancer cells, did not
actually do so and failed to prolong survival in patients with pancreatic cancer compared to a standard therapy. Following this news, NewLink stock dropped to $5.05 per share, or 30.61%, to close at $11.45 on May 10, 2016.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!nlnk/omiv7. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in NewLink you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 440161

NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares or otherwise acquired the common stock of DeVry Education Group Inc. (“DeVry” or the “Company”) (NYSE: DV) between February 4, 2011 and January 27, 2016, inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts, including: (1) DeVry University was involved in a multi-year deceptive marketing and advertising campaign; (2) DeVry University exaggerated its students’ ability to find employment after graduation (3) DeVry University exaggerated its graduates’ prospective income; (4) consequentially, DeVry overelaborated its growth, revenue, and earnings potential by hiding the truthful employment opportunities of its graduates to the investing public and potential students.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!dv/yhxi8. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in DeVry you have until July 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441226

NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court, District of Massachusetts on behalf of those who purchased shares of Chiasma, Inc. (“Chiasma” or the “Company”) (NASDAQ: CHMA) between July 15, 2015 and April 17, 2016 inclusive (the “Class Period”).

Chiasma is a biopharmaceutical company focused on developing and commercializing orphan medications to better meet the needs of patients and healthcare professionals.

Chiasma’s leading product is oral octreotide, Mycapssa, used to treat acromegaly, a condition resulting from excess growth
hormone. As of June 2015, Chiasma had finished its multinational Phase 3 clinical trial of Mycapssa and submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for approval to market and sell Mycapssa. On or about July 15, 2016, Chiasma completed its IPO, issuing 6.4 million shares and raising approximately $102 million of net proceeds.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Chiasma’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Chiasma’s Phase 3 clinical trial for Mycapssa was not adequate to show effectiveness and for FDA approval; (2) Chiasma’s management of its suppliers was not adequate to avoid mistakes, thus delaying FDA approval; and (3) consequentially, Chiasma’s public statements were materially false and misleading at all relevant times.

On April 18, 2016, premarket, Chiasma announced that the FDA had issued a Complete Response Letter for Mycapssa’s NDA, explaining that the FDA did not see ample proof of efficacy to warrant approval and advising the Company to conduct another clinical trial to address this deficiency. The FDA also listed its apprehensions about certain aspects of the Company’s single-arm, open-label Phase 3 clinical trial and strongly recommended a randomized, double-blind and controlled trial that enrolls patients from the United States and for a long enough duration to ensure that control of disease activity is stable at the time point selected for the primary efficacy assessment. The FDA instructed that certain deficiencies that were found at a recent site inspection would also need to be resolved before approval.

Following this news, Chiasma stock dropped $6.42 per share, or 63.13%, to close at $3.75 on April 18, 2016.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!chma/ts6n9. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Chiasma you have until August 8, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441186

NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against HCP, Inc. (“HCP” or “the Company”) (NYSE: HCP). The class action has been filed on behalf of a class consisting of all persons or entities who purchased HCP from March 30, 2015 through February 8, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that Defendants violated securities laws by misleading investors and failing to disclose that during the class one HCP’s chief clients, ManorCare, was engaged in extensive billing fraud that may have generated roughly $6 billion in false settlement claims, and that the value of HCP’s interest in ManorCare was dubious.

On April 21, 2015, HCP revealed that the U.S. Department of Justice had intervened in whistleblower lawsuits. On May 5, 2015, HCP reported a $478 million non-cash impairment charge in connection with its lease arrangements with ManorCare. On February 9, 2016, HCP revealed that its equity stake in ManorCare had been written down to zero, and that it had taken an $836 million non-cash impairment on its ManorCare lease assets and placed all of its ManorCare real estate assets on a “Watch List.”

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!hcp/cv82w. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in DS Healthcare you have until July 11,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441223

NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Sunrun, Inc. (“Sunrun” or the “Company”) (NASDAQ: RUN). The class action has been filed
on behalf of a class consisting of all persons or entities who purchased SunRun pursuant or traceable to the Company’s Registration Statement and its Prospectus issued in connection with the Company’s Initial Public Offering (the “Offering” or “IPO”), which commenced on or about August 5, 2015.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Sunrun provides residential solar electricity and operates the “second largest fleet of residential solar energy systems” in the United States.

Around March 27, 2015, Sunrun filed its registration statement, Form S-l, with the United States Securities and Exchange Commission (the “SEC”), which was amended and later listed as effective by the SEC (the “Registration Statement”). In the meantime, Nevada lawmakers rejected a request from Sunrun and other rooftop solar companies, to increase the number from a 3% of consumers who can participate in net metering solar programs. On August 5, 2015, Sunrun sold 17.9 million stocks at $14.00 per share in its initial public offering (the “IPO”), raising over $250 million. Once news that Sunrun’s growth relied on multifaceted debt arrangements and investors realized it was unlikely to withstand its revenues forecast leading up to the IPO, Sunrun stock dropped $4.96 per share and closed at $7.15 per share on April 14, 2016.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about Sunrun’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (a) Sunrun’s operating costs were being understated by not recognizing and disclosing the fixed grid costs being borne for it by public utilities where net metering programs were being employed; (b) Sunrun had been overcharging electricity rates that it was selling to its net metering customers; (c) conflicting with its Registration Statement, Sunrun stated its customers were dispersed across 15 states and the District of Columbia in, when in truth it had a substantial 20% customer concentration in Nevada alone; (d) Sunrun’s likelihood to continue to sign customers to 20-year contracts–which would lower the fixed costs for installing solar systems in houses–was at risk due to the ongoing regulatory review of net metering programs in 20 of the 40 states that then legalized net metering; (e) because Sunrun was employing an irrationally low discount rate of 6% in calculating the value of it retained assets, it was exaggerating their value; and (f) as a result of the above mentioned, at the time of the IPO, the Sunrun’s business and financial prospects were misleading to the investing public.

Following this news that Sunrun could not sustain the revenues the Company forecasted leading up to the IPO, Sunrun dropped as low as $4.86 per share, to close at $7.50 per share on May 6, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!run/kmin8. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Sunrun you have until July 5, 2016 to request that the Court appoint you as lead plaintiff.
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 440151

NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against TransEntrix, Inc. (“TransEntrix” or “the Company”) (NYSE MKT: TRXC). The class action has been filed in the United States District Court, Eastern District of North Carolina, on behalf of a class consisting of all persons or entities who purchased TransEntrix securities during the period between February 10, 2016 and May 10, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements or failed to disclose adverse information regarding key aspects of the Company’s business. Specifically, the complaint alleges defendants failed to disclose deficiencies within the Company’s 510(k) submission regarding the SurgiBot that undermined the likelihood that the SurgiBot would receive FDA clearance, which would leave the Company unable to commercialize the SurgiBot in 2016 and would impair the Company’s ability to obtain approval for and commercialize its other robotic surgery platform in the United States. As a result of these false statements and/or omissions, TransEnterix common stock traded at artificially inflated prices during the Class Period.

On April 20, 2016 post-market, TransEnterix announced that the Food and Drug Administration (“FDA”) informed the Company on the previous day, April 19, 2016, that it has determined that “SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission.” Following this news, TransEnterix’s stock dropped as much as $2.99, or 63.08%, to just $1.75 in after-hours trading on April 20, 2016.

Then on May 20, 2016, the Company issued a press release stating that it “expect[ed] to have further discussion with the FDA, but currently believes that a new 510(k) submission would be required to obtain clearance,” that it was reprioritizing its near-term regulatory efforts to focus on another submission, and that, as a result, it “ha[d] taken actions to reduce headcount and investment related to the SurgiBot.”

Following this news, the price of TransEnterix fell 10% to close at $1.84 per share on May 11, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator, Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in TransEntrix you have until August 1,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441219

NEW YORK, NY / ACCESSWIRE / June 24, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CPI Card Group, Inc. (“CPI” or the “Company”) (NASDAQ: PMTS) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired CPI common stock in connection with CPI’s October 8, 2015 initial public offering (“IPO”), including purchasers of the common stock in the aftermarket.

CPI is a prominent provider of electronic payment cards and associated services, offering a single source for credit, debit and prepaid debit cards, including “EMV” (Europay, MasterCard and Visa) chip, personalization, instant issuance, fulfillment and mobile payment services.

The complaint alleges that at the time of the IPO, CPI had shipped over 100 million cards more than shipped in the second quarter and first part of the third quarter of 2015. Unbeknownst to investors at the time, this shipment created a massive backlog with those customers, which significantly reduced the demand for additional card shipments in the fourth quarter of 2015 and fiscal 2016. The unfavorable dealings and uncertainties linked with CPI’s largest customers’ inventory levels were likely to impact on CPI’s profitability and, therefore, should have been disclosed in the Registration Statement.

CPI sold 17.25 million shares of common stock during its IPO at $10 per share, raising $172.5 million. At the time the complaint was filed, CPI common stock was trading at about $4.70 per share 53% less than the IPO price.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!cpi/edd1e or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in CPI and purchased the common stock in or pursuant to CPI’s October 8, 2015 IPO, including purchasers of the common stock in the aftermarket (the “Class”) you have until August 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441290

LONDON, UK / ACCESSWIRE / June 24, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Information Technology Services industry. Companies recently under review include Xerox, International Business Machines, Fidelity National Information Services, and Accenture. See our complete report on Xerox at:

http://www.activewallst.com/registration-3/?symbol=XRX

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/

Despite a slowdown in the Technology sector this year, demand for Information Technology Services remains high. Let us see how this is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at:

http://www.activewallst.com/register/

ActiveWallSt.com takes a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions.

Xerox Corp. (NYSE: XRX)

Norwalk, Connecticut headquartered Xerox Corp.’s shares climbed 2.45% and finished Thursday’s trading session at $10.02. A total volume of 3.24 million shares was traded. In the last one month, the stock has advanced 7.97%. The Company’s shares are trading above their 50-day and 200-day moving averages by 1.31% and 0.73%, respectively. Moreover, shares of Xerox, which provides business process and document management solutions globally, have a Relative Strength Index (RSI) of 56.20.

International Business Machines Corp. (NYSE: IBM)

On Thursday, shares in Armonk, New York headquartered International Business Machines Corp. recorded a trading volume of 3.96 million shares, which was above their three months average volume of 3.78 mission shares. The stock ended the session 1.59% higher at $155.35. The Company’s shares have gained 4.75% in the last one month, 6.02% in the previous three months, and 15.14% since the start of this year. The stock is trading 4.03% above its 50-day moving average and 11.42% above its 200-day moving average. Furthermore, shares of International Business Machines, which provides information technology products and services globally, have an RSI of 63.20. The complimentary research report on IBM can be turned on at:

http://www.activewallst.com/registration-3/?symbol=IBM

Fidelity National Information Services Inc. (NYSE: FIS)

Shares in Jacksonville, Florida headquartered financial services technology Company, Fidelity National Information Services Inc. closed the day at $73.91, gaining 1.07%. The stock recorded a trading volume of 1.60 million shares. The Company’s shares have advanced 0.36% in the last one month, 18.45% over the previous three months, and 22.91% on an YTD basis. The stock is trading 4.21% above its 50-day moving average and 13.45% above its 200-day moving average. Additionally, shares of Fidelity National Information Services, which offers a range of solutions in retail and enterprise banking, payments, capital markets, asset and wealth management, risk and compliance, treasury, and insurance, have an RSI of 59.08. Register for free and access key information on FIS at:

http://www.activewallst.com/registration-3/?symbol=FIS

Accenture PLC (NYSE: ACN)

At the closing bell yesterday, shares in Dublin, Ireland-based Accenture PLC ended 0.10% lower at $118.91. A total volume of 2.86 million shares was traded, which was higher than their three months average volume of 2.16 million shares. The stock has advanced 5.04% in the previous three months and 14.89% since the start of this year. The Company’s shares are trading above their 50-day and 200-day moving averages by 1.92% and 11.94%, respectively. Furthermore, shares of Accenture, which provides management consulting, technology, and outsourcing services globally, have an RSI of 55.18. ACN research are available for free at:

http://www.activewallst.com/registration-3/?symbol=ACN

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441600

LONDON, UK / ACCESSWIRE / June 24, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Electronic Equipment industry. Companies recently under review include Apple, Sony, Koninklijke Philips, and Harman Intl. Industries. See our complete report on Apple at:

http://www.activewallst.com/registration-3/?symbol=AAPL

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/

The Electronic Equipment industry continues to experience a slowdown this year. ActiveWallSt.com accesses how this is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at

http://www.activewallst.com/register/

Let us take a brief technical look at how each of the companies mentioned above have performed at the close yesterday and over the last few trading sessions.

Apple Inc. (NASDAQ: AAPL)

At the close on Thursday, shares in Cupertino, California headquartered Apple Inc. rose 0.58%, ending the day at $96.10. The stock recorded a trading volume of 32.00 million shares. The Company’s shares are trading below their 50-day moving average by 2.10%. Moreover, shares of Apple, which designs, manufactures, and markets mobile communication and media devices, personal computers, and portable digital music players to consumers, small and mid-sized businesses, education, and enterprise and government customers globally, have a Relative Strength Index (RSI) of 41.24. On June 23rd, 2016, research firm Canaccord Genuity reiterated its ‘Buy’ rating with a decrease of the target price to $120 a share from $130 a share for the Company’s stock.

Sony Corp. (NYSE: SNE)

Shares in Tokyo, Japan headquartered Sony Corp. ended the day 1.36% higher at $29.00 and with a total volume of 827,983 shares traded. In the last month and the previous three months, the stock has gained 4.17% and 13.86%, respectively. Moreover, the Company’s shares have advanced 17.84% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.37% and 14.38%, respectively. Furthermore, shares of Sony, which designs, develops, manufactures, and sells electronic equipment, instruments, and devices for consumer, professional, and industrial markets globally, have an RSI of 61.35. The complimentary research on SNE can be downloaded at:

http://www.activewallst.com/registration-3/?symbol=SNE

Koninklijke Philips N.V. (NYSE: PHG)

On Thursday, shares in Amsterdam, the Netherlands-based Koninklijke Philips N.V. finished 3.02% higher at $26.96. A total volume of 1.36 million shares was traded, which was above their three months average volume of 1.19 million shares. The stock has advanced 2.86% in the last one month, 1.30% over the previous three months, and 9.62% since the start of this year. The Company’s shares are trading above their 50-day and 200-day moving averages by 2.67% and 6.39%, respectively. Additionally, shares of Koninklijke Philips, which engages in healthcare, consumer lifestyle, and lighting businesses globally, have an RSI of 61.01. Register for free and access the latest research report on PHG at:

http://www.activewallst.com/registration-3/?symbol=PHG

Harman International Industries Inc. (NYSE: HAR)

Stamford, Connecticut headquartered Harman International Industries Inc.’s shares recorded a trading volume of 756,804 shares at the end of yesterday’s session and closed the day at $76.83, gaining 2.29%. The stock has advanced 0.76% in the last one month. The Company’s shares are trading below their 50-day moving average by 1.51%. Additionally, shares of Harman International Industries, which designs, engineers, manufactures, and markets audio, visual, and infotainment systems; and enterprise automation solutions and software services for consumers, automakers, and enterprises globally, have an RSI at 46.30. On June 14th, 2016, research firm Northcoast initiated a ‘Buy’ rating for the Company’s stock. The complete research on HAR is available for free at:

http://www.activewallst.com/registration-3/?symbol=HAR

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441602